Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Gilead Sciences, Inc. (GILD) Stock Sees Market Value Hit $117.09 billion: What Are the Implications?
Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $93.95 which represents a slight increase of $0.55 or 0.59% from the prior close of $93.4. The stock opened at $93 and touched a low of $92.
Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock
Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address unmet medical needs in the United States, Europe and internationally. It will report its Q4 2024 earnings on Feb.
Gilead Sciences Inc. stock rises Tuesday, still underperforms market
Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.10% to 6,
Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade
Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the past five years and becoming the most valuable company in the world for a brief period (it's currently No.
Zacks.com on MSN16h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...
Hosted on MSN6d
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
STAT6d
Gilead plans to halt free access to an HIV drug, worrying patient advocates
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...
Gilead Sciences (GILD) Made Big Announcements in Q3
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...
bovnews3d
Gilead Sciences, Inc. (GILD) Stock Surge: The Transparent Factors Exposed
Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...
ETF Daily News13d
Gilead Sciences’ (GILD) Neutral Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report ...
Business Insider13d
Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis
(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion ...
Morningstar2d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Pharma Letter6d
Gilead invests in Assembly Bio to advance clinical programs
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional ...